![In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer— But at FDA “Maybe” has meaning](https://cdn.cancerletter.com/media/2017/09/tie-web2.jpg)
![In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer— But at FDA “Maybe” has meaning](https://cdn.cancerletter.com/media/2017/09/tie-web2.jpg)
Cover Story
In a 6-6 vote, ODAC says “maybe” to Sutent for adjuvant kidney cancer—
But at FDA “Maybe” has meaningWith frustrating photo finish voting results—6-6—still on the screen, FDA's cancer czar Richard Pazdur delivered an acerbic thank-you to members of the agency's Oncologic Drugs Advisory Committee:“Well, that's the end vote, it makes our job definitely easier,” said Pazdur, director of the FDA's Oncology Center of Excellence, who gets sarcastic sometimes.
In Brief
Drugs & Targets
Trending Stories
- Before the Olympics were smoke-free, tobacco brand deals ran rampant
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- Kamala Harris widely expected to continue Cancer Moonshot; Conservatives present their vision in Project 2025
- Solving problems doctors can’t fix: How Georgetown’s medical-legal partnership saves lives by including lawyers on cancer care teams
Why every cancer center needs a Cancer LAW Project - ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications
- In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch